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INTRODUCTION
Globally, Indigenous populations, which
include Aboriginal and Torres Strait
islanders in Australia and Ma¯ori people
in New Zealand (NZ), have poorer health
than their non-Indigenous counterparts
(1). Indigenous peoples worldwide face
substantial challenges in poverty, educa-
tion, employment, housing, and discon-
nection from ancestral lands (1). While
addressing social determinants of health is
a priority, solving clinical issues is equally
important. Indeed, ignoring the latter until
social issues improve risks further disparity
as this may take generations. A systematic
overview of interventions addressing social
determinants of health found a striking
lack of reliable evaluations (2). Where evi-
dence was available, health improvement
associated with interventions was modest
or uncertain (2). Thus, advances in health-
care remain essential and these require
the best evidence available in preventing
and managing common illnesses, including
respiratory illnesses.
THE IMPORTANCE OF RESPIRATORY
HEALTH IN CHILDHOOD
Relative to its substantial disease bur-
den, lung health receives little attention
worldwide compared with other condi-
tions, which attract substantially more
media attention and support from research
funding bodies. Yet, pneumonia remains
the most important cause of mortality
and morbidity in young children globally
(3, 4). By 2020, chronic obstructive pul-
monary disease (COPD) is expected to
be the third-ranked cause of mortality in
the world (5). Moreover, COPD, thought
previously to occur only in smokers, is rec-
ognized increasingly in non-smoking indi-
viduals (5, 6). Indeed, those with non-
smoking-related COPD may have poorer
clinical outcomes (higher hospitalizations
for COPD and pneumonia) than smoking-
related COPD (6). Non-smoking-related
COPD is associated with childhood respi-
ratory infections, as is bronchiectasis (7).
The latter often goes under-recognized as
29–50% of people with severe COPD (8),
and as many as 40% of patients with diffi-
cult to control asthma and chronic cough,
have bronchiectasis (9).
To reduce chronic pulmonary disease in
adults, interventions during critical phases
of lung development in early childhood
and even in the pre and ante-natal peri-
ods may be necessary (10–12). Unlike
some other organs, the lungs continue to
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develop throughout early childhood (13).
Furthermore, pulmonary immunity and
respiratory phenotype are influenced by
gene–environment interactions early in life
(including in utero) (14). If lung function
is already decreased in infancy, this can
persist (track) throughout childhood and
predict future respiratory morbidity (15).
Indeed, there is increasing evidence that
much adult lung disease [such as COPD
(6) and bronchiectasis] originates in child-
hood (where it is potentially preventable)
(16, 17).
There are few published Australian data
on the changes in the epidemiology and
burden of lung health in Indigenous chil-
dren and adults. Between 2001 and 2012,
the overall mortality of respiratory-related
deaths declined, by up to 32% in adult
males, but respiratory disease still accounts
for 8% of the health-gap in mortality
between Indigenous and non-Indigenous
Australians (18). Infant mortality [respi-
ratory illness is second only to congeni-
tal conditions as a cause of death in this
age group (19)] has also declined in Aus-
tralia, but chronic respiratory diseases are
being identified increasingly (20). Whether
this is related to improved case ascer-
tainment or an increased in prevalence
is unknown. In NZ, comparable data are
unavailable, but acute admissions (which
in children are mainly from respiratory
infections) for infectious diseases increased
between 1989–93 and 2004–08 from 20.5 to
26.6% of all hospitalizations (21). This was
accompanied by an increasing disparity in
the burden of infectious diseases experi-
enced by Ma¯ori where the age-standardized
rate ratio for hospitalization was 2.15 (95%
CI 2.14–2.16) compared with European
and other non-Pacific groups (21).
Currently, in nation-wide data for
Indigenous Australians, respiratory disor-
ders are the most common reason for gen-
eral practice encounters, the second most
prevalent self-reported chronic condition
and the second most common cause for
hospitalization (22). In NZ, mirroring the
situation with infectious diseases, respira-
tory hospitalizations for Ma¯ori children
are almost twice that for European and
other non-Pacific ethnic groups (23). To
help reduce the disparity of lung health in
Australian and NZ Indigenous children, a
partnership involving Indigenous leaders,
pediatric and adult clinicians, laboratory
scientists, and educationalists was formed
in November 2012 under the umbrella of
the Centre of Research Excellence (CRE) in
Indigenous Children’s Lung Health, funded
by the National Health of Medical Research
Council (Australia). Our overarching aim
is to improve the lung health of children,
particularly Indigenous children, through
research. Here, we describe our frame-
work and key discussions from our sec-
ond workshop that brought together part-
ners of our CRE, external experts, and
higher degree research scholars involved
in projects linked with the CRE, whose
emblem is displayed in Figure S1 in Sup-
plementary Material.
THE CONCEPTUAL FRAMEWORK FOR
DEVELOPING SEVERE
BRONCHIECTASIS AND COPD
Our simplified framework for the devel-
opment and progression of bronchiecta-
sis and/or COPD in adults is presented
in Figure 1. The idea that recurrent acute
respiratory infections (ARIs) and subse-
quent bronchiectasis can be prevented is
not new (24, 25). In the 1940–50s, astute
clinicians described a “pre-bronchiectatic
state,” which can lead to irreversible lung
disease if not well managed (25). They
also recognized that persistent or recurrent
lower airway infections were associated
with developing bronchiectasis (24).
The alveolar stage of human lung devel-
opment begins at 36-weeks gestation
and continues for ~7 years post-natally
(13). Insults in the first few years of life,
when post-natal lung development is the
most important, are thus likely to have
FIGURE 1 | A simplified diagram on the development of severe lung disease in adulthood (blue) and the possible factors (yellow) that likely influence
the progression of disease. COPD, chronic obstructive pulmonary disease; CSLD, chronic suppurative lung disease; ETS, environmental tobacco smoke
exposure.
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long-term effects. While low birth weight
can influence future lung function, there
is increasing evidence that early life events
(e.g., ARIs) are equally important determi-
nants of adult lung dysfunction, as shown
in both animal and human studies (26–
29). Therefore, interventions that reduce
ARIs in Indigenous children would be
expected to have both short and poten-
tial long-term benefits, especially as severe
and recurrent ARIs are independent risk
factors for subsequent COPD (26, 27) and
bronchiectasis (7).
Chronic suppurative lung disease
(CSLD) in children is a specific clini-
cal phenotype involving symptoms and
signs of chronic endobronchial purulence
accompanied by persistent or recurrent
wet cough and airway inflammation,
with or without radiographic evidence
of bronchiectasis (30). The limitations
of radiographic diagnosis, particularly in
children (17, 31), are recognized. In the
Northern Territory (NT, Australia), the
incidence of CSLD in the first year of life
is 118/100,000; (32) while the national
incidence of radiographically confirmed
bronchiectasis in the NZ population aged
<15 years is 3.7/100,000, twice that of cystic
fibrosis (33). In Central Australian Abo-
riginal children (34) and Alaskan Native
children (35), CSLD affects one in every
63–68 children (~1500/100,000), yet there
are few resources directed at prevention,
clinical management, and research. Deaths
are uncommon in children (36), although
in NZ a 2% mortality rate as a direct
result of bronchiectasis was reported from
a single tertiary center (37). In contrast,
a substantial proportion of Indigenous
Australian adults with bronchiectasis die
in their fourth decade of life (38).
In adults, the link between COPD and
bronchiectasis is increasingly appreciated
(39). Those with severe COPD are more
likely to have bronchiectasis (40). Further-
more, bronchiectasis in children and adults
is often missed or misdiagnosed as asthma
(9, 41), as chronic cough in the general pop-
ulation is dismissed frequently as unim-
portant. We found recently that >20%
of children with chronic cough (>4 weeks
duration) had seen a doctor >20 times
before referral and receiving appropriate
treatment (42). Among Indigenous people
in Australia, chronic cough is often “nor-
malized,” in contrast to non-Indigenous
Australians (43).
Based on the above framework, our
approach to achieve improvements in lung
health relevant to Indigenous child health
focuses on intervention points that are
feasible in the clinical context. Our CRE-
related projects encompass various aspects
relevant to CSLD (Figure 1); most are listed
online1. Here, we highlight key discussions
points from our recent workshop.
INDIGENOUS VOICES AND THE
PARADIGM OF RESEARCH AND CARE
The approach within our CRE projects
is concurrent health education for child
caregivers, using culturally sensitive meth-
ods, and participation is informed and
supported, leading to very high reten-
tion rates in randomized controlled tri-
als (RCTs) (44). Projects are accompanied
by knowledge translation plans reviewed
and endorsed by an Advisory Board (see
text footnote 1). An Indigenous Reference
Group (IRG) also provides advice before
commencing projects. The IRG remain
informed throughout the projects and, on
its closure, advises on how to provide
feedback2.
Our projects have also improved com-
munity engagement (45). In NZ, whanau
(families) of children with bronchiectasis
are a driving force leading to Ma¯ori com-
munity leaders developing an inaugural
website for the purpose of providing educa-
tion and support for all families with chil-
dren similarly affected. The children them-
selves are being encouraged to tell their own
stories about their health online. It is hoped
that this will be a platform, which will con-
tinue to improve awareness and generate
increased resourcing for this patient group.
However, more can always be done. Indige-
nous leaders of the group challenged us to
take further steps, such as examining the
role of traditional healers and medicines
in our research, adopting an approach to
“take your mob with you,” improving the
consent process for Indigenous carers, tak-
ing into account intergenerational effects
and extending our influence beyond lung
health. The importance of the work and
voices of the four Indigenous higher degree
research scholars were highlighted at the
workshop.
While a perception remains that Indige-
nous populations are “over-researched,”
in reality there are few RCTs relevant
to ethnic disparities in clinical outcomes
(46). Indeed, major funding bodies (e.g.,
The National Institutes of Health, USA)
now have policies to ensure that minority
groups and women are included in all clin-
ical trials (47). Given the relative paucity
of strategies for recruiting and retaining
Indigenous people in RCTs (48), McCal-
lum and colleagues’ study, where >97% of
Indigenous children were retained in a RCT
(44), is a model that should be extended to
other studies.
HOST–PATHOGEN INTERACTION IN
BRONCHIECTASIS – THE MANY
QUESTIONS
There are many clinical and research gaps
relating to the pathogenesis and manage-
ment of CSLD, including bronchiectasis.
This year’s scientific component of the
workshop focused largely on the interac-
tions between the lower airways micro-
biome, host defense mechanisms, and
clinical factors relevant to children with
CSLD/bronchiectasis.
Few studies have addressed the host–
pathogen interaction in children with, or
at risk of, CSLD. Pizzutto et al (49) found
that children with CSLD have an altered
systemic cell-mediated immune response
to non-typeable Haemophilus influenzae
(NTHi) strains in vitro. The peripheral
blood mononuclear cells of 80 children
with CSLD and 51 controls were stimulated
with antigens and mitogens and cytokine
responses measured (49). The major find-
ing was that those with CSLD produced sig-
nificantly less interferon-gamma (IFN-γ)
in response to NTHi than healthy controls.
This deficient IFN-γ response may con-
tribute to increased susceptibility to NTHi
infections and to the pathogenesis of CSLD
in children. Findings from a larger group
of children found that this deficit can be
partially corrected by immunization with
1http://www.menzies.edu.au/page/Research/Centres_initiatives_and_projects/Centre_for_Research_Excellence_Lung_health/
2http://www.menzies.edu.au/page/About_Us/Board_and_Menzies_committees/Indigenous_Reference_Group/
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a licensed pneumococcal-NTHI protein
D-conjugate vaccine (50). NTHi is partic-
ularly important in CSLD/bronchiectasis
(51) and COPD (52) as it is the most
common bacteria cultured from the lower
airways of children and adults with both
diseases.
Whether variants of the genetically
diverse NTHi or other pathogens have dif-
ferent virulence strategies in relation to
the airway response is unknown. Such
data are important for future vaccine
development, especially as epidemiologi-
cally unrelated NTHi isolates lacking pro-
tein D have been detected in Indigenous
population (53). Delineating evolution-
ary changes within the bacterial genome
over time and relating this to differential
host responses and disease severity remain
elusive. Clinical outcome data associat-
ing deficits in T-cell function is another
research gap. Further, although relating
host responses to a single pathogen is use-
ful for understanding the pathogenesis of
CSLD and COPD, this is only a small
component of the overall host–pathogen
interaction. Increasingly, the complexity of
the lower airway pathobiology is being
understood, such as the contribution of
the airway microbiome, biofilms (54), local
innate and adaptive immune responses,
the influence of antibiotics upon bacte-
rial communities, and the physiological
stresses imposed by the lung microenviron-
ment (55).
Data relating to microbiota in human
health and disease are increasing exponen-
tially. However, many challenges remain for
respiratory studies, such as specimen types
and handling (56), sampling the lower air-
ways in young children, and differentiat-
ing cause and effect. Longitudinal cohort
studies relating microbiota composition to
clinical outcomes and inflammation are
needed. The role of host tolerance to mem-
bers of the microbiota within the respira-
tory tract is also unknown. The relative
clinical significance of core versus satel-
lite microbiota, the interaction of the pul-
monary microbiome with respect to invad-
ing respiratory viruses and oral and gut
microbiota, and the roles of these to the
pathogenesis of CSLD/bronchiectasis have
yet to be studied. Additionally, the con-
cept of mucosal immunization (57) and/or
probiotics (58) protecting against ARIs is
intriguing.
OTHER STUDIES AND THE NEED FOR
STUDIES ADDRESSING PREVENTION
Our current work has an increased focus
on primary and secondary/tertiary pre-
vention and treatment strategies, as out-
lined on our CRE website. Examples
include earlier detection of disease through
improving follow-up of children post-
hospitalization and improving the treat-
ment for bronchiectasis to prevent or to
minimize the progression of lung disease.
The importance of the latter was acknowl-
edged by our CRE, particularly with
tobacco smoking. Once smoking becomes
established, it is difficult to discontinue. If
individuals avoid smoking during adoles-
cence, it is unlikely that they will take it up
later (59), while in contrast the probabil-
ity of quitting is inversely proportional to
the age of initiation (60). Indeed, a home-
visit based RCT, using a culturally sensi-
tive approach undertaken by Indigenous
workers in Australia and Ma¯ori workers in
NZ, was unsuccessful in reducing tobacco
smoke exposure of Indigenous children
when compared to routine care (61).
SUMMARY
Addressing health issues in childhood is
needed to reduce the long-term impair-
ment and social disadvantage in adults.
This paradigm is striking for lung health
for many reasons, including the impact
of respiratory infections and environmen-
tal insults upon post-natal lung develop-
ment, which increase the risk of future lung
disease, such as COPD and bronchiecta-
sis. We have briefly presented our frame-
work for the development of severe COPD
and/or bronchiectasis (Figure 1) and our
model of research and care. In our sec-
ond annual workshop, we also highlighted
several questions concerning the airway
microbiome and related host responses in
children with CSLD/bronchiectasis.
Through our CRE, we have built part-
nerships with Indigenous leaders, scien-
tists, and clinicians working toward a com-
mon goal of reducing disparity though
high-quality science and care. While we
are beginning to improve lung health
in Indigenous children through several
projects addressing various clinically fea-
sible interventions, much work is still to be
done in reducing disparity in lung health
between Indigenous and non-Indigenous
Australian and NZ peoples.
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